Revenue: As of FY2026 Q1, the actual value is USD 1.1 M.EPS: As of FY2026 Q1, the actual value is USD -2.11.EBIT: As of FY2026 Q1, the actual value is USD -784 K.Arcadia Biosciences, Inc. operates as a single reportable segment, with all financial data pertaining to this segment .<h4>Segment Revenue</h4>Product revenue for the three months ended March 31, 2026, was $1,100 thousand, representing a decrease of - $100 thousand, or -8%, compared to $1,200 thousand in the same period of 2025. This decrease was primarily due to a revenue reserve release of approximately $193,000 in 2025 that was not present in 2026 .<h4>Operational Metrics</h4><ul><li>Cost of Revenues: Increased by $18 thousand, or 3%, to $700 thousand for the three months ended March 31, 2026, from $682 thousand in the prior year period, primarily due to higher Zola volume and increased product and freight expenses .</li><li>Gain on sale of intangible assets: No gain was recognized for the three months ended March 31, 2026, compared to a gain of $750 thousand in the same period of 2025 from the sale of patent portfolios .</li><li>Change in fair value of contingent consideration: There was no change in fair value for the three months ended March 31, 2026, compared to a gain of $1,000 thousand in the prior year period .</li><li>Selling, general, and administrative expenses: Decreased by - $559 thousand, or -32%, to $1,179 thousand for the three months ended March 31, 2026, from $1,738 thousand in the same period of 2025, mainly due to the absence of M&amp;A fees and lower employee costs .</li><li>Interest income: Decreased to $5 thousand for the three months ended March 31, 2026, from $207 thousand in the prior year period .</li><li>Other loss, net: An other loss, net of - $1,504 thousand was recognized for the three months ended March 31, 2026, primarily due to an unrealized loss on Above Food Ingredients, Inc. common stock, with no such loss in the prior year .</li><li>Loss on January 2026 Inducement Offer: A loss of - $2,877 thousand was recognized for the three months ended March 31, 2026, related to the fair value of preferred investment options and the increase in fair value from the reduction in exercise price of warrants and options .</li><li>Change in fair value of common stock warrant and option liabilities: Resulted in a gain of $1,191 thousand for the three months ended March 31, 2026, compared to a gain of $1,862 thousand in the same period of 2025 .</li><li>Issuance and offering costs: Totaled - $421 thousand for the three months ended March 31, 2026, related to the January 2026 Inducement Offer .</li><li>Net (loss) income attributable to common stockholders: Arcadia Biosciences, Inc. reported a net loss of - $4,385 thousand for the three months ended March 31, 2026, a significant change from the net income of $2,599 thousand in the same period of 2025 .</li></ul><h4>Cash Flow</h4><ul><li>Net cash used in operating activities: Was - $1,099 thousand for the three months ended March 31, 2026, compared to - $1,588 thousand for the same period in 2025 .</li><li>Net cash provided by investing activities: Was $0 for the three months ended March 31, 2026, compared to $500 thousand in 2025 .</li><li>Net cash provided by financing activities: Was $1,794 thousand for the three months ended March 31, 2026, primarily from the January 2026 Inducement Offer, compared to $5 thousand in 2025 .</li><li>Cash and cash equivalents: As of March 31, 2026, cash and cash equivalents stood at $954 thousand, increasing from $259 thousand at December 31, 2025 .</li></ul><h4>Unique Metrics</h4><ul><li>Accumulated deficit: As of March 31, 2026, the accumulated deficit was - $285,602 thousand, an increase from - $281,217 thousand at December 31, 2025 .</li></ul><h4>Future Outlook and Strategy</h4>Arcadia Biosciences, Inc. believes its current cash and cash equivalents are insufficient for the next 12 months, indicating substantial doubt about its ability to continue as a going concern . The company plans to seek additional funding through debt or equity financings or by selling assets, including shares of Above Food Ingredients, Inc . However, there is no guarantee that funding will be secured or that asset sales will generate significant net proceeds due to market conditions .

Arcadia Biosciences | 10-Q: FY2026 Q1 Revenue: USD 1.1 M